MIAMI, Feb. 16, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended December 31, 2022 after the close of the U.S. financial markets on Thursday, February 23, 2023. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on February 23rd beginning at 4:30 p.m. Eastern time.
CONFERENCE CALL & WEBCAST INFORMATION
OPKO encourages participants to pre-register for the conference call using this link. Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Participants may register at any time, including up to and after the call start time. Those unable to pre-register may participate by dialing (833) 630-0584 (U.S.) or (412) 317-1815 (International). A webcast of the call can also be accessed at OPKO’s Investor Relations page and here.
A telephone replay will be available until March 2, 2023 by dialing (877) 344-7529 (U.S.) or (412) 317-0088 (International) and providing the passcode 3187296. A webcast replay will be available beginning approximately one hour after the completion of the live conference call here.
About OPKO Health
OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com.
Contacts:
LHA Investor Relations
Yvonne Briggs, 310-691-7100
This email address is being protected from spambots. You need JavaScript enabled to view it.
or
Bruce Voss, 310-691-7100
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.47 |
Daily Volume: | 0 |
Market Cap: | US$989.020M |
November 18, 2024 November 14, 2024 October 07, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB